Related Experiment Videos
Budipine in Parkinson's tremor
1Department of Neurology, University of Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany. heinz.reichmann@mailbox.tu-dresden.de
Journal of the Neurological Sciences
|June 21, 2006
Summary
Budipine offers a broad spectrum of action for Parkinsonian tremor, a challenging symptom to treat. Despite past concerns about QT interval prolongation, it remains a useful and safe option for managing Parkinson
Area of Science:
- Neurology
- Pharmacology
Background:
- Tremor-dominant idiopathic Parkinson's disease (PD) progresses slower than rigid-akinetic PD.
- Treating Parkinsonian tremor is a significant clinical challenge.
- Current treatments include anticholinergics, beta-blockers, clozapine, dopaminergic agents, and deep brain stimulation.
Purpose of the Study:
- To evaluate the efficacy and safety of budipine in treating Parkinsonian tremor and other PD symptoms.
- To explore the potential benefits of budipine's non-dopaminergic mechanism of action.
Main Methods:
- Review of open and double-blind studies involving budipine.
- Assessment of budipine as both monotherapy and adjunct therapy.
- Consideration of historical data regarding budipine and QT interval prolongation.
Main Results:
- Budipine demonstrated beneficial effects in patients, irrespective of whether used as monotherapy or adjunct therapy.
- The drug exhibits a broad spectrum of action, exceeding that of other anti-Parkinsonian drugs.
- Its non-dopaminergic action may benefit patients on stable dopaminergic medication.
Conclusions:
- Budipine is considered a highly useful and safe medication for managing tremor and other primary symptoms of Parkinson's disease.
- Despite previous concerns regarding QT prolongation, careful application allows for its continued therapeutic use.